Largest Manufacturer of Water Soluble Films Revenue Surges 110% QoQ as Commercialisation Drives Profit Growth

Arrow Greentech Ltd, which operates across water-soluble films, security products, intellectual property-led technologies and pharmaceutical applications, reported a strong improvement in financial performance in Q1FY27.

Revenue from operations stood at Rs 87.80 crore, rising 110 per cent quarter-on-quarter (QoQ). EBITDA increased 246 per cent QoQ to Rs 35.90 crore, while the EBITDA margin expanded to 41 per cent. Profit after Tax (PAT) rose 269.6 per cent QoQ to Rs 27.40 crore. The sharper increase in profitability compared with revenue indicates improved operating leverage during the quarter.

The management attributed the performance to the commercialisation of investments made in manufacturing capacity, research and development (R&D) and intellectual property (IP). The key monitorable going ahead will be whether the company can sustain the improved margins and revenue growth across subsequent quarters.

Arrow Greentech's security products business provides anti-counterfeit solutions for high-security papers, brand protection and related applications. The company supplies paper manufacturers and also produces anti-counterfeit currency threads. According to the company document, Arrow Greentech is currently the only manufacturer of such threads in India and supplies them to the Reserve Bank of India.

Water-soluble films remain another core business area, with applications spanning packaging, healthcare, agriculture, textiles and consumer goods. The company has a global portfolio of more than 50 patents, of which 21 are currently in force. Additional patent applications are under process in India and overseas. The eventual contribution from these patents will depend on the company's ability to commercialise them through licensing or the production of patented products.

Arrow Greentech's wholly owned subsidiary, Avery Pharmaceuticals, focuses on oral drug-delivery products using embedded water-soluble film technology and also operates as a specialised contract development and manufacturing organisation (CDMO). However, pharmaceutical commercialisation typically involves longer development cycles and regulatory timelines.

Going forward, investors will need to monitor the sustainability of the 41 per cent EBITDA margin, consistency in revenue growth and the pace at which R&D and IP investments translate into commercial opportunities. While Q1FY27 marked a significant improvement in financial performance, results from the coming quarters will provide greater clarity on the sustainability of this growth.

Disclaimer: The article is for informational purposes only and not investment advice.